{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:45:47Z","timestamp":1778917547398,"version":"3.51.4"},"reference-count":48,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0022_s_001_w2aab3b7b3b1b6b1aab1c17b1Aa\">\n                    <jats:title id=\"d2883964e6521_w2aab3b7b3b1b6b1aab1c17b1aAa\">Background<\/jats:title>\n                    <jats:p>There is great variability in the uptake of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of colorectal peritoneal metastases (CRPM) in Australia and New Zealand. This study aims to provide a snapshot of perceptions among colorectal surgeons in the management of CRPM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0022_s_002_w2aab3b7b3b1b6b1aab1c17b2Aa\">\n                    <jats:title id=\"d2883964e6530_w2aab3b7b3b1b6b1aab1c17b2aAa\">Methods<\/jats:title>\n                    <jats:p>A structured ten-question online survey was sent to all colorectal surgeons, with three questions on clinical experience and demographics, one on health economics and six on hypothetical clinical scenarios. Scores were collated and reported based on Likert scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0022_s_003_w2aab3b7b3b1b6b1aab1c17b3Aa\">\n                    <jats:title id=\"d2883964e6539_w2aab3b7b3b1b6b1aab1c17b3aAa\">Results<\/jats:title>\n                    <jats:p>Eighty-one respondents (36.2%) completed the survey. Most surgeons (66.7%) strongly disagreed with offering CRS and HIPEC at all hospitals. The majority (87.7%) agreed that CRS and HIPEC offered a higher survival benefit than systemic chemotherapy in pseudomyxoma peritonei (PMP), and 69.1% in CRPM (comparators: 60.5% ovarian cancer, 14.8% gastric cancer). There were mixed strategies in managing low-volume, isolated peritoneal recurrences. The majority did not recommend second-look laparoscopy, but favoured operative management of Krukenberg tumours. In the presence of incidental peritoneal metastases, only 29.6% favoured biopsy only and referring the patient to a peritoneal disease centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0022_s_004_w2aab3b7b3b1b6b1aab1c17b4Aa\">\n                    <jats:title id=\"d2883964e6548_w2aab3b7b3b1b6b1aab1c17b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>Response rate was relatively low. In Australia and New Zealand, colorectal surgeons see a strong role for CRS and HIPEC in the management of PMP and CRPM. The role of \u201csecond look\u201d surgery in high-risk cases is controversial and not supported. Krukenberg tumours are viewed as surgical disease. Regular updates and collaboration with peritoneal centres may help surgeons stay abreast with latest evidence in the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0022","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T05:17:16Z","timestamp":1572499036000},"source":"Crossref","is-referenced-by-count":5,"title":["Perceptions in the management of colorectal peritoneal metastases: A bi-national survey of colorectal surgeons"],"prefix":"10.1515","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8964-3082","authenticated-orcid":false,"given":"Vignesh","family":"Narasimhan","sequence":"first","affiliation":[{"name":"Department of Surgery , Peter MacCallum Cancer Centre , Melbourne , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Warrier","sequence":"additional","affiliation":[{"name":"Department of Surgery , Peter MacCallum Cancer Centre , Melbourne , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Michael","sequence":"additional","affiliation":[{"name":"Department of Surgery , Peter MacCallum Cancer Centre , Melbourne , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"McCormick","sequence":"additional","affiliation":[{"name":"Department of Surgery , Peter MacCallum Cancer Centre , Melbourne , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ramsay","sequence":"additional","affiliation":[{"name":"Department of Surgery , Peter MacCallum Cancer Centre , Melbourne , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Surgery , Peter MacCallum Cancer Centre , Melbourne , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Heriot","sequence":"additional","affiliation":[{"name":"Department of Surgery , Peter MacCallum Cancer Centre , Melbourne , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"2025120909222922653_j_pp-2019-0022_ref_001_w2aab3b7b3b1b6b1ab1b6b1Aa","doi-asserted-by":"crossref","unstructured":"Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et\u2009al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016;17:1709\u201319.2774392210.1016\/S1470-2045(16)30500-9","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"2025120909222922653_j_pp-2019-0022_ref_002_w2aab3b7b3b1b6b1ab1b6b2Aa","doi-asserted-by":"crossref","unstructured":"Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989;63:364\u20137.291044410.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V"},{"key":"2025120909222922653_j_pp-2019-0022_ref_003_w2aab3b7b3b1b6b1ab1b6b3Aa","doi-asserted-by":"crossref","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et\u2009al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358\u201363.10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O10640968","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"2025120909222922653_j_pp-2019-0022_ref_004_w2aab3b7b3b1b6b1ab1b6b4Aa","doi-asserted-by":"crossref","unstructured":"Verwaal V, van Ruth S, de Bree E, van Slooten G, van Tinteren H, Boot H, et\u2009al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737\u201343.1455129310.1200\/JCO.2003.04.187","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2025120909222922653_j_pp-2019-0022_ref_005_w2aab3b7b3b1b6b1ab1b6b5Aa","doi-asserted-by":"crossref","unstructured":"Banaste N, Rousset P, Mercier F, Rieussec C, Valette PJ, Glehen O, et\u2009al. Preoperative nutritional risk assessment in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis. Int J Hyperthermia 2018;34:589\u201394.2882889710.1080\/02656736.2017.1371342","DOI":"10.1080\/02656736.2017.1371342"},{"key":"2025120909222922653_j_pp-2019-0022_ref_006_w2aab3b7b3b1b6b1ab1b6b6Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et\u2009al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63\u20138.1991786310.1200\/JCO.2009.23.9285","DOI":"10.1200\/JCO.2009.23.9285"},{"key":"2025120909222922653_j_pp-2019-0022_ref_007_w2aab3b7b3b1b6b1ab1b6b7Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et\u2009al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681\u20135.10.1200\/JCO.2008.19.716019103728","DOI":"10.1200\/JCO.2008.19.7160"},{"key":"2025120909222922653_j_pp-2019-0022_ref_008_w2aab3b7b3b1b6b1ab1b6b8Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et\u2009al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284\u201392.1531077110.1200\/JCO.2004.10.012","DOI":"10.1200\/JCO.2004.10.012"},{"key":"2025120909222922653_j_pp-2019-0022_ref_009_w2aab3b7b3b1b6b1ab1b6b9Aa","doi-asserted-by":"crossref","unstructured":"Quenet F, Goere D, Mehta S, Roca L, Dumont F, Heississen M, et\u2009al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 2011;254:294\u2013301.2177212910.1097\/SLA.0b013e3182263933","DOI":"10.1097\/SLA.0b013e3182263933"},{"key":"2025120909222922653_j_pp-2019-0022_ref_010_w2aab3b7b3b1b6b1ab1b6c10Aa","doi-asserted-by":"crossref","unstructured":"Chua T, Morris D, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:1330\u20136.2003332110.1245\/s10434-009-0866-x","DOI":"10.1245\/s10434-009-0866-x"},{"key":"2025120909222922653_j_pp-2019-0022_ref_011_w2aab3b7b3b1b6b1ab1b6c11Aa","doi-asserted-by":"crossref","unstructured":"Prada-Villaverde A, Esquivel J, Lowy A, Markman M, Chua T, Pelz J, et\u2009al. The American society of peritoneal surface malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 2014;110:779\u201385.10.1002\/jso.2372825088304","DOI":"10.1002\/jso.23728"},{"key":"2025120909222922653_j_pp-2019-0022_ref_012_w2aab3b7b3b1b6b1ab1b6c12Aa","doi-asserted-by":"crossref","unstructured":"Bernaiche T, Emery E, Bijelic L. Practice patterns, attitudes, and knowledge among physicians regarding cytoreductive surgery and HIPEC for patients with peritoneal metastases. Pleura Peritoneum 2018;3:1\u20137.","DOI":"10.1515\/pp-2017-0025"},{"key":"2025120909222922653_j_pp-2019-0022_ref_013_w2aab3b7b3b1b6b1ab1b6c13Aa","doi-asserted-by":"crossref","unstructured":"Braam HJ, Boerma D, Wiezer MJ, Ramshorst B. Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists. Int J Clin Oncol 2015;20:928\u201334.10.1007\/s10147-015-0816-5","DOI":"10.1007\/s10147-015-0816-5"},{"key":"2025120909222922653_j_pp-2019-0022_ref_014_w2aab3b7b3b1b6b1ab1b6c14Aa","unstructured":"Nikolic S, Dzodic R, Zegarac M, Djurisic I, Gavrilovic D, Vojinovic V, et\u2009al. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience. J Buon 2014;19:66\u201374.24659645"},{"key":"2025120909222922653_j_pp-2019-0022_ref_015_w2aab3b7b3b1b6b1ab1b6c15Aa","unstructured":"Rajeev R, Klooster B, Turaga KK. Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion. J Gastrointest Oncol 2016;7:122\u20138.26941990"},{"key":"2025120909222922653_j_pp-2019-0022_ref_016_w2aab3b7b3b1b6b1ab1b6c16Aa","doi-asserted-by":"crossref","unstructured":"van Gijn W, Gooiker GA, Wouters MW, Post PN, Tollenaar RA, van de Velde CJ. Volume and outcome in colorectal cancer surgery. Eur J Surg Oncol 2010;36:S55\u201363.2061564910.1016\/j.ejso.2010.06.027","DOI":"10.1016\/j.ejso.2010.06.027"},{"key":"2025120909222922653_j_pp-2019-0022_ref_017_w2aab3b7b3b1b6b1ab1b6c17Aa","doi-asserted-by":"crossref","unstructured":"Kusamura S, Baratti D, Deraco M. Mutidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg 2012;255:348\u201356.10.1097\/SLA.0b013e3182436c28","DOI":"10.1097\/SLA.0b013e3182436c28"},{"key":"2025120909222922653_j_pp-2019-0022_ref_018_w2aab3b7b3b1b6b1ab1b6c18Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et\u2009al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy \u2013 a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol 2007;14:2270\u201380.1746454310.1245\/s10434-007-9406-8","DOI":"10.1245\/s10434-007-9406-8"},{"key":"2025120909222922653_j_pp-2019-0022_ref_019_w2aab3b7b3b1b6b1ab1b6c19Aa","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et\u2009al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386\u2013422.10.1093\/annonc\/mdw23527380959","DOI":"10.1093\/annonc\/mdw235"},{"key":"2025120909222922653_j_pp-2019-0022_ref_020_w2aab3b7b3b1b6b1ab1b6c20Aa","doi-asserted-by":"crossref","unstructured":"Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR. The American society of colon and rectal surgeons clinical practice guidelines for the treatment of colon cancer. Dis Colon Rectum 2017;60:999\u20131017.10.1097\/DCR.000000000000092628891842","DOI":"10.1097\/DCR.0000000000000926"},{"key":"2025120909222922653_j_pp-2019-0022_ref_021_w2aab3b7b3b1b6b1ab1b6c21Aa","doi-asserted-by":"crossref","unstructured":"Franko J, Shi Q, Goldman C, Pockaj B, Nelson G, Goldberg R, et\u2009al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012;30:263\u20137.2216257010.1200\/JCO.2011.37.1039","DOI":"10.1200\/JCO.2011.37.1039"},{"key":"2025120909222922653_j_pp-2019-0022_ref_022_w2aab3b7b3b1b6b1ab1b6c22Aa","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et\u2009al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340.10.1056\/NEJMoa170861829342393","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909222922653_j_pp-2019-0022_ref_023_w2aab3b7b3b1b6b1ab1b6c23Aa","doi-asserted-by":"crossref","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et\u2009al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34\u201343.10.1056\/NEJMoa05298516394300","DOI":"10.1056\/NEJMoa052985"},{"key":"2025120909222922653_j_pp-2019-0022_ref_024_w2aab3b7b3b1b6b1ab1b6c24Aa","doi-asserted-by":"crossref","unstructured":"Farrell R. Is peritonectomy and hyperthermic intraperitoneal chemotherapy a new standard of treatment for advanced epithelial ovarian cancer? Aust NZ J Obstet Gynaecol 2019;59:335\u201340.10.1111\/ajo.12953","DOI":"10.1111\/ajo.12953"},{"key":"2025120909222922653_j_pp-2019-0022_ref_025_w2aab3b7b3b1b6b1ab1b6c25Aa","doi-asserted-by":"crossref","unstructured":"Ceelen W, Nieuwenhove Y, Putte D, Pattyn P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol 2014;21:3023\u20138.10.1245\/s10434-014-3713-724756812","DOI":"10.1245\/s10434-014-3713-7"},{"key":"2025120909222922653_j_pp-2019-0022_ref_026_w2aab3b7b3b1b6b1ab1b6c26Aa","doi-asserted-by":"crossref","unstructured":"Waite K, Youssef H. The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review. Ann Surg Oncol 2017;24:705\u201320.10.1245\/s10434-016-5712-328058545","DOI":"10.1245\/s10434-016-5712-3"},{"key":"2025120909222922653_j_pp-2019-0022_ref_027_w2aab3b7b3b1b6b1ab1b6c27Aa","unstructured":"Rovers KP, Bakkers C, Simkens G, Burger JW, Nienhuijs SW, Creemers GM, et\u2009al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II\u2013III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19:390.31023318"},{"key":"2025120909222922653_j_pp-2019-0022_ref_028_w2aab3b7b3b1b6b1ab1b6c28Aa","doi-asserted-by":"crossref","unstructured":"Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et\u2009al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018;36:LBA3503.","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503"},{"key":"2025120909222922653_j_pp-2019-0022_ref_029_w2aab3b7b3b1b6b1ab1b6c29Aa","doi-asserted-by":"crossref","unstructured":"Honor\u00e9 C, Gelli M, Francoual J, Benhaim L, Elias D, Go\u00e9r\u00e9 D. Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer? Int J Hyperthermia 2017;33:505\u201310.2854083110.1080\/02656736.2017.1306119","DOI":"10.1080\/02656736.2017.1306119"},{"key":"2025120909222922653_j_pp-2019-0022_ref_030_w2aab3b7b3b1b6b1ab1b6c30Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Goere D, Di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, et\u2009al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008;247:445\u201350.1837618810.1097\/SLA.0b013e31815f0113","DOI":"10.1097\/SLA.0b013e31815f0113"},{"key":"2025120909222922653_j_pp-2019-0022_ref_031_w2aab3b7b3b1b6b1ab1b6c31Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Honore C, Dumont F, Ducreux M, Boige V, Malka D, et\u2009al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011;254:289\u201393.10.1097\/SLA.0b013e31822638f621709543","DOI":"10.1097\/SLA.0b013e31822638f6"},{"key":"2025120909222922653_j_pp-2019-0022_ref_032_w2aab3b7b3b1b6b1ab1b6c32Aa","doi-asserted-by":"crossref","unstructured":"Goere D, Glehen O, Quenet F, Ducreux M, Guilloit J, Texier M, et\u2009al. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-NTC01226394). J Clin Oncol 2018;36:3531.10.1200\/JCO.2018.36.15_suppl.3531","DOI":"10.1200\/JCO.2018.36.15_suppl.3531"},{"key":"2025120909222922653_j_pp-2019-0022_ref_033_w2aab3b7b3b1b6b1ab1b6c33Aa","doi-asserted-by":"crossref","unstructured":"Klaver C, Wisselink D, Punt C, Snaebjornsson P, Crezee J, Aalbers A, et\u2009al. Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: primary outcome of the COLOPEC multicenter randomized trial. J Clin Oncol 2019;37:482.10.1200\/JCO.2019.37.4_suppl.482","DOI":"10.1200\/JCO.2019.37.4_suppl.482"},{"key":"2025120909222922653_j_pp-2019-0022_ref_034_w2aab3b7b3b1b6b1ab1b6c34Aa","doi-asserted-by":"crossref","unstructured":"Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006;243:212\u201322.10.1097\/01.sla.0000197702.46394.1616432354","DOI":"10.1097\/01.sla.0000197702.46394.16"},{"key":"2025120909222922653_j_pp-2019-0022_ref_035_w2aab3b7b3b1b6b1ab1b6c35Aa","doi-asserted-by":"crossref","unstructured":"Kuijpers AM, Mehta AM, Aalbers AG, van Driel WJ, Boot H, Verwaal VJ. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2014;40:937\u201342.2463092310.1016\/j.ejso.2014.02.238","DOI":"10.1016\/j.ejso.2014.02.238"},{"key":"2025120909222922653_j_pp-2019-0022_ref_036_w2aab3b7b3b1b6b1ab1b6c36Aa","doi-asserted-by":"crossref","unstructured":"Evers DJ, Verwaal VJ. Indication for oophorectomy during cytoreduction for intraperitoneal metastatic spread of colorectal or appendiceal origin. Br J Surg 2011;98:287\u201392.2104668010.1002\/bjs.7303","DOI":"10.1002\/bjs.7303"},{"key":"2025120909222922653_j_pp-2019-0022_ref_037_w2aab3b7b3b1b6b1ab1b6c37Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker P, Averbach A. Krukenberg syndrome as a natural manifestation of tumor cell entrapment. Cancer Treat Res 1996;82:163\u201391.884995010.1007\/978-1-4613-1247-5_11","DOI":"10.1007\/978-1-4613-1247-5_11"},{"key":"2025120909222922653_j_pp-2019-0022_ref_038_w2aab3b7b3b1b6b1ab1b6c38Aa","doi-asserted-by":"crossref","unstructured":"Bushati M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y, et\u2009al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol 2018;44:1942\u20138.10.1016\/j.ejso.2018.07.003","DOI":"10.1016\/j.ejso.2018.07.003"},{"key":"2025120909222922653_j_pp-2019-0022_ref_039_w2aab3b7b3b1b6b1ab1b6c39Aa","doi-asserted-by":"crossref","unstructured":"Jayne D, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89:1545\u201350.1244506410.1046\/j.1365-2168.2002.02274.x","DOI":"10.1046\/j.1365-2168.2002.02274.x"},{"key":"2025120909222922653_j_pp-2019-0022_ref_040_w2aab3b7b3b1b6b1ab1b6c40Aa","doi-asserted-by":"crossref","unstructured":"Lemmens V, Klaver Y, Verwaal V, Rutten H, Coebergh J, de Hingh I. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011;128:2717\u201325.2071516710.1002\/ijc.25596","DOI":"10.1002\/ijc.25596"},{"key":"2025120909222922653_j_pp-2019-0022_ref_041_w2aab3b7b3b1b6b1ab1b6c41Aa","doi-asserted-by":"crossref","unstructured":"Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012;99:699\u2013705.10.1002\/bjs.867922287157","DOI":"10.1002\/bjs.8679"},{"key":"2025120909222922653_j_pp-2019-0022_ref_042_w2aab3b7b3b1b6b1ab1b6c42Aa","doi-asserted-by":"crossref","unstructured":"Hentzen J, Rovers KP, Kuipers H, van der Plas WY, Been LB, Hoogwater FJ, et\u2009al. Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a multicenter, retrospective, observational study. Ann Surg Oncol 2019;26:2210\u201321.3087749510.1245\/s10434-019-07294-y","DOI":"10.1245\/s10434-019-07294-y"},{"key":"2025120909222922653_j_pp-2019-0022_ref_043_w2aab3b7b3b1b6b1ab1b6c43Aa","doi-asserted-by":"crossref","unstructured":"Maillet M, Glehen O, Lambert J, Goere D, Pocard M, Msika S, et\u2009al. Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol 2016;23:863\u20139.2648084810.1245\/s10434-015-4914-4","DOI":"10.1245\/s10434-015-4914-4"},{"key":"2025120909222922653_j_pp-2019-0022_ref_044_w2aab3b7b3b1b6b1ab1b6c44Aa","doi-asserted-by":"crossref","unstructured":"Rivard J, McConnell Y, Temple W, Mack L. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit? J Surg Oncol 2014;109:104\u20139.10.1002\/jso.2344624449172","DOI":"10.1002\/jso.23446"},{"key":"2025120909222922653_j_pp-2019-0022_ref_045_w2aab3b7b3b1b6b1ab1b6c45Aa","doi-asserted-by":"crossref","unstructured":"Shida D, Tsukamoto S, Ochiai H, Kanemitsu Y. Long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2018;25:173\u20138.2906329510.1245\/s10434-017-6133-7","DOI":"10.1245\/s10434-017-6133-7"},{"key":"2025120909222922653_j_pp-2019-0022_ref_046_w2aab3b7b3b1b6b1ab1b6c46Aa","doi-asserted-by":"crossref","unstructured":"Grass F, Martin D, Montemurro M, Mathevet P, Wolfer A, Coukos G, et\u2009al. Current opinion and knowledge on peritoneal carcinomatosis: a survey among a Swiss oncology network. Chemother 2018;63:143\u20137.10.1159\/000488774","DOI":"10.1159\/000488774"},{"key":"2025120909222922653_j_pp-2019-0022_ref_047_w2aab3b7b3b1b6b1ab1b6c47Aa","doi-asserted-by":"crossref","unstructured":"Yoo HJ, Hong JJ, Ko YB, Lee M, Kim Y, Han HY, et\u2009al. Current practices of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies: an international survey of oncologic surgeons. World J Surg Oncol 2018;16:92.2976444510.1186\/s12957-018-1377-7","DOI":"10.1186\/s12957-018-1377-7"},{"key":"2025120909222922653_j_pp-2019-0022_ref_048_w2aab3b7b3b1b6b1ab1b6c48Aa","doi-asserted-by":"crossref","unstructured":"Spiegle G, Schmocker S, Huang H, Victor JC, Law C, McCart JA, et\u2009al. Physicians\u2019 awareness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer carcinomatosis. Can J Surg 2013;56:237\u201342.2388349310.1503\/cjs.003912","DOI":"10.1503\/cjs.003912"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/4\/article-20190022.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0022\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0022\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:57:29Z","timestamp":1765277849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0022\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,11,2]]},"published-print":{"date-parts":[[2019,11,26]]}},"alternative-id":["10.1515\/pp-2019-0022"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0022","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,30]]},"article-number":"20190022"}}